Expectant, medical and surgical ectopic management

Management begins only after diagnosis and stability assessment. A PUL with an empty uterus and abnormal hCG is not automatically eligible for methotrexate: NICE states it should be offered on a first visit only when ectopic pregnancy is definitively diagnosed and a viable intrauterine pregnancy excluded. Pregnancy intention, future fertility, treatment burden, contraindications and the patient’s preference matter, but a ruptured or unstable ectopic requires life-saving surgery.

Expectant management is an active monitoring plan, not no treatment. NICE offers it to a clinically stable, pain-free patient with a tubal ectopic smaller than 35 mm, no visible heartbeat, hCG 1,000 IU/L or lower and capacity to return. It may be considered when hCG is above 1,000 and below 1,500 IU/L if all other criteria apply. Explain that urgent admission may still be required if symptoms develop and provide 24-hour access.

For expectant care, repeat serum hCG on days 2, 4 and 7 after the original test. If each value falls by at least 15% from the previous value, continue weekly until a negative result below 20 IU/L. If it falls by less than 15%, plateaus or rises, reassess clinically and seek senior advice about methotrexate or surgery. Symptoms override any scheduled test. Limited evidence suggests similar resolution, rupture, additional-treatment, psychological and future-fertility outcomes to medical management in appropriately selected patients.

Systemic methotrexate is a folate antagonist that stops proliferating trophoblast. NICE offers it when there is no significant pain, an unruptured tubal ectopic smaller than 35 mm with no heartbeat, hCG below 1,500 IU/L, no intrauterine pregnancy and reliable follow-up. A common single-dose regimen is 50 mg/m² intramuscularly. Confirm consent and baseline FBC, renal and liver function and check contraindications before administration.

Methotrexate is unsuitable in haemodynamic instability, rupture, clinically important hepatic or renal dysfunction, blood dyscrasia, immunodeficiency, active pulmonary disease, peptic ulcer disease, breastfeeding, concurrent viable intrauterine pregnancy or inability to follow up. Review medicines and folate supplements. Advise avoiding folic acid, alcohol, intercourse and vigorous activity during resolution according to local protocol, avoiding NSAIDs where advised, and avoiding pregnancy for at least three months after treatment.

After methotrexate, check hCG on days 4 and 7, then weekly until negative. Many protocols require at least a 15% decline from day 4 to day 7; plateau or rise prompts clinical reassessment and possible repeat dose or surgery. Transient pain can occur several days after injection, but rupture cannot be diagnosed as expected separation pain without examination. About 15% require a second dose and about 7% surgery in RCOG patient data.

When hCG is at least 1,500 but below 5,000 IU/L, offer either methotrexate or surgery if the patient remains stable without significant pain, the mass is under 35 mm with no heartbeat, no intrauterine pregnancy is seen and follow-up is reliable. Explain that further intervention is more likely after methotrexate. Surgery is first-line at hCG 5,000 or more, with a mass at least 35 mm, visible heartbeat, significant pain or unreliable follow-up.

Laparoscopy is preferred when feasible. Salpingectomy removes the affected tube and is offered unless other infertility risks make conservation important. Salpingotomy removes the ectopic while retaining the tube and may be considered when the contralateral tube is damaged, but persistent trophoblast, recurrent ectopic and further treatment are more likely. Explain that up to one in five may need methotrexate or salpingectomy afterwards.

Follow-up differs by surgery. After salpingotomy, measure hCG at day 7 and weekly until negative. After salpingectomy, NICE advises a urine pregnancy test at three weeks and reassessment if positive. Apply June 2026 anti-D rules: none up to 11+6 weeks; at 12+0 to 12+6 weeks offer at least 250 IU to an RhD-negative patient having medical or surgical management. Provide histology information, future early-scan access, contraception or conception advice and bereavement support.